Source-checked decision dossier
FormBlends vs Hims: Price, Medication Path, and Support Compared
A primary-source comparison of FormBlends and Hims, including price structure, medication status, and unresolved fields.
Bottom line
How do FormBlends and Hims differ for a buyer choosing an online GLP-1 provider?
FormBlends emphasizes access to compounded prescriptions with product-page starting prices. Hims uses a different medication and pricing model: FDA-approved Novo Nordisk GLP-1 access announced in 2026. The better fit depends on medication status, complete cost, support, and whether the buyer prefers an FDA-approved or compounded path.
Primary-source comparison
Every row links to the provider or regulator used. “Verify” means the public source did not establish that field clearly enough to score it.
| Option | Medication path | Published pricing | Membership structure | Provider review | Unverified fields |
|---|---|---|---|---|---|
| FormBlends | Compounded prescriptions shown | Semaglutide $99; tirzepatide $349 | No separate fee shown on product finder | Required | Dose-based changes and complete checkout terms |
| Hims | FDA-approved Novo Nordisk GLP-1 access announced in 2026 | Starting at $149; verify complete current checkout price | Verify current terms | Required | State eligibility and final patient-specific price |
Claims and evidence
Each claim carries its own scope, verification date, and source—not a generic bibliography at the bottom of the page.
FormBlends publishes $99 for compounded semaglutide and $349 for compounded tirzepatide on its product finder.
- FormBlends: Product Finder: GLP-1 Programs & Peptide Research Accessed 2026-08-25.
Hims publishes this current price structure: Starting at $149; verify complete current checkout price.
- Hims & Hers: Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers Accessed 2026-08-25.
The FormBlends and Hims offers should not be ranked from a single headline price because the medication path and required fees differ.
- FormBlends: Product Finder: GLP-1 Programs & Peptide Research Accessed 2026-08-25.
- Hims & Hers: Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers Accessed 2026-08-25.
Reproducible methodology
How this page was built
- 1.Use provider, manufacturer, and regulator pages as primary sources; do not score claims copied from review sites.
- 2.Record the exact access date and distinguish starting prices, ongoing prices, membership fees, medication fees, and dose-dependent pricing.
- 3.Treat any field that cannot be reproduced from a primary source as not verified instead of estimating it.
- 4.Recheck volatile price and availability claims at least monthly and retain a public change log.
Verification
Last checked 2026-08-25. This page uses 2 disclosed sources and preserves unresolved fields as “not verified.”
Commercial disclosure
FormBlends sells telehealth programs and may benefit when a reader chooses FormBlends. Competitors are evaluated from their own published materials. Payment or affiliate relationships do not affect inclusion or source status.
Next decision